SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • July 2nd, 2021 • Essetifin SPA • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 28, 2021, between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively, the “Purchasers”).
REGENERX BIOPHARMACEUTICALS, INC. WARRANT TO PURCHASE COMMON STOCKEssetifin SPA • July 6th, 2023 • Pharmaceutical preparations • Delaware
THIS CERTIFIES THAT, for value received, Essetifin S.p.A., or its permitted registered assigns (the “Holder”), is entitled to subscribe for and purchase at the Exercise Price (defined below) from REGENERX BIOPHARMACEUTICALS, INC., a Delaware corporation (the “Company”) up to 3,750,000 shares of the common stock of the Company, par value $0.001 per share (the “Common Stock”). This Warrant has been issued pursuant to that certain Securities Purchase Agreement between the Company and the Holder dated of even date herewith (the “Purchase Agreement”).
REGENERX BIOPHARMACEUTICALS, INC. CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT July 3, 2023Convertible Note and Warrant Purchase Agreement • July 6th, 2023 • Essetifin SPA • Pharmaceutical preparations
THIS CONVERTIBLE NOTE AND WARRANT PURCHASE AGREEMENT (this “Agreement”), dated as of July 3, 2023 is entered into by and between RegeneRx Biopharmaceuticals, Inc., a Delaware corporation (the “Company”), and Essetifin S.p.A., an Italian corporation (the “Investor”).
JOINT FILING AGREEMENTJoint Filing Agreement • July 2nd, 2021 • Essetifin SPA • Pharmaceutical preparations
The undersigned hereby agree that the Schedule 13D with respect to the Common Stock of RegeneRx Biopharmaceuticals, Inc. dated as of July 2, 2021, is, and any amendments thereto signed by such of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934.
JOINT FILING AGREEMENTJoint Filing Agreement • July 6th, 2023 • Essetifin SPA • Pharmaceutical preparations
The undersigned hereby agree that the Schedule 13D with respect to the Common Stock of RegeneRx Biopharmaceuticals, Inc. dated as of July 6, 2023, is, and any amendments thereto signed by such of the undersigned shall be, filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended.
